This possibility is supported by the fact that many studies have recently demonstrated that tumours which are most sensitive to Cdk4/6 inhibitors are proficient for Rb [42], [43], suggesting that these kinases drive tumour proliferation in the context of wild-type Rb activity. This evidence concerns the gene RB1 and neoplasm.